PURPOSE: The purpose of this study was to investigate the incidence of fosaprepitant-associated infusion site adverse events (ISAEs) among a cohort of breast cancer patients receiving doxorubicin/cyclophosphamide (AC) chemotherapy. METHODS: A retrospective review of electronic medical record (EMR) data was performed for all patients who were initiated on AC from January 2011 to April 2012. Data collected included baseline demographics, antiemetic regimen, documentation of ISAEs, and type of intravenous (IV) access. Descriptive statistics (mean and standard deviation or percentages) were summarized overall, by type of IV access and initial antiemetic given. RESULTS: Among the 148 patients included in this analysis, 98 initially received fosaprepitant and 44 received aprepitant. The incidence of ISAEs associated with fosaprepitant administration was 34.7 % (n=34), while the incidence of aprepitant-associated ISAEs was 2.3 % (n=1). All ISAEs were associated with peripheral IV access. The most commonly reported ISAEs were infusion site pain (n=26), erythema (n=22), swelling (n=12), superficial thrombosis (n=8), infusion site hives (n=5), and phlebitis/thrombophlebitis (n=5). Twenty-six patients experienced more than one type of ISAE. CONCLUSIONS: The incidence and severity of ISAEs associated with fosaprepitant administration among a group of patients receiving AC chemotherapy are significant and appreciably higher than what has been previously reported.
PURPOSE: The purpose of this study was to investigate the incidence of fosaprepitant-associated infusion site adverse events (ISAEs) among a cohort of breast cancerpatients receiving doxorubicin/cyclophosphamide (AC) chemotherapy. METHODS: A retrospective review of electronic medical record (EMR) data was performed for all patients who were initiated on AC from January 2011 to April 2012. Data collected included baseline demographics, antiemetic regimen, documentation of ISAEs, and type of intravenous (IV) access. Descriptive statistics (mean and standard deviation or percentages) were summarized overall, by type of IV access and initial antiemetic given. RESULTS: Among the 148 patients included in this analysis, 98 initially received fosaprepitant and 44 received aprepitant. The incidence of ISAEs associated with fosaprepitant administration was 34.7 % (n=34), while the incidence of aprepitant-associated ISAEs was 2.3 % (n=1). All ISAEs were associated with peripheral IV access. The most commonly reported ISAEs were infusion site pain (n=26), erythema (n=22), swelling (n=12), superficial thrombosis (n=8), infusion site hives (n=5), and phlebitis/thrombophlebitis (n=5). Twenty-six patients experienced more than one type of ISAE. CONCLUSIONS: The incidence and severity of ISAEs associated with fosaprepitant administration among a group of patients receiving AC chemotherapy are significant and appreciably higher than what has been previously reported.
Authors: Kenneth C Lasseter; Jay Gambale; Bo Jin; Art Bergman; Marvin Constanzer; James Dru; Tae H Han; Anup Majumdar; Judith K Evans; M Gail Murphy Journal: J Clin Pharmacol Date: 2007-05-24 Impact factor: 3.126
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Bernardo L Rapoport; Karin Jordan; Judith A Boice; Arlene Taylor; Carole Brown; James S Hardwick; Alexandra Carides; Timothy Webb; Hans-Joachim Schmoll Journal: Support Care Cancer Date: 2009-07-01 Impact factor: 3.603
Authors: Steven Grunberg; Daniel Chua; Anish Maru; José Dinis; Suzanne DeVandry; Judith A Boice; James S Hardwick; Elizabeth Beckford; Arlene Taylor; Alexandra Carides; Fausto Roila; Jørn Herrstedt Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Jørn Herrstedt; Hyman B Muss; David G Warr; Paul J Hesketh; Peter D Eisenberg; Harry Raftopoulos; Steven M Grunberg; Munir Gabriel; Anthony Rodgers; Carolyn M Hustad; Kevin J Horgan; Franck Skobieranda Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland Journal: Oncologist Date: 2019-12-04
Authors: Livia T Hegerova; Alexis D Leal; Darryl C Grendahl; Drew K Seisler; Kristine M Sorgatz; Kari J Anderson; Crystal R Hilger; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-06-26 Impact factor: 3.603
Authors: Emily N Larsen; Nicole Marsh; Catherine O'Brien; Emily Monteagle; Christopher Friese; Claire M Rickard Journal: Support Care Cancer Date: 2020-07-24 Impact factor: 3.603
Authors: C Weinstein; K Jordan; S A Green; E Camacho; S Khanani; E Beckford-Brathwaite; W Vallejos; L W Liang; S J Noga; B L Rapoport Journal: Ann Oncol Date: 2015-10-08 Impact factor: 32.976